晶胺稳定性的现象学模型
Bartek Lisowski1, Seweryn Ulaszek2,3, Barbara Wiśniowska4
1Chair of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, Kraków, Poland. bartek.lisowski@uj.edu.pl.
Scientific reports
|January 9, 2026
概括
转氨基粉症 (TTR) 的动力稳定剂可能通过影响其清除或合成来增加TTR水平,而不仅仅是通过防止四聚合物解离. 需要进一步的研究来理解这些复杂的TTR恒温机制.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 计算生物学 计算生物学
背景情况:
- 晶体氨酸 (TTR) 粉症是由错误折叠的TTR单体形成粉样纤维引起的.
- 动力稳定剂 (例如,tafamidis) 旨在防止TTR四相解离,这是疾病发病过程中的关键步骤.
- 临床观察显示稳定剂治疗后TTR水平增加,这一现象需要解释.
研究的目的:
- 调查在动力稳定剂治疗期间观察到的TTR水平增加背后的机制.
- 为了确定是否降低了TTR,仅仅是四聚体解离能解释了TTR水平的升高.
- 探索影响TTR稳态的替代机制,例如改变清除,合成或单体去除.
主要方法:
- 开发和应用一个简单的现象学模型.
- 药理动力学和药理动力学数据的整合.
- 实验观察结果的分析.
主要成果:
- 这项研究探讨了减少的TTR解离是否足够解释TTR水平的增加.
- 研究了其他机制,包括改变细胞内化,降解,合成 (药物监护) 和单体重组.
- 该模型提供了对TTR恒温的洞察.
结论:
- 仅仅减少分离可能无法完全解释使用稳定剂增加的TTR水平.
- 稳定剂可能会影响TTR清除和合成途径.
- 该研究强调了简化模型在确定TTR研究关键问题的有用性.
相关概念视频
Energy to Drive Translocation
2.6K
Mitochondrial protein import is powered by two distinct energy sources: ATP hydrolysis and electrochemical potential across the inner membrane. Newly synthesized precursors are bound by cytosolic chaperones of the Hsp70 family, which guide them to the import receptors on the mitochondrial surface. Utilizing the energy of ATP hydrolysis, Hsp70 chaperones transfer these precursors to the TOM receptors on the mitochondrial outer membrane.
Generally, polypeptides are unfolded by two distinct...
Generally, polypeptides are unfolded by two distinct...
2.6K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
269
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
269


